Shanghai - Delayed Quote CNY

HENGRUI PHARMA (600276.SS)

51.23
+0.54
+(1.07%)
At close: 3:00:04 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
NameTitlePayExercisedYear Born
Mr. Hong Bin Dai GM & Director -- -- 1976
Mr. Jianjun Liu Chief Financial Officer -- -- 1979
Mr. Jie Ping Sun Deputy GM & Director -- -- 1970
Dr. Lian Shan Zhang Ph.D. Deputy GM & Director -- -- 1962
Dr. Ningjun Jiang M.D., Ph.D. Deputy GM & Director -- -- 1961
Ms. Xiao Han Liu Secretary of the Board of Directors -- -- 1985
Mr. Ya Ping Shen Deputy General Manager -- -- 1964
Mr. Cheng Liao Deputy General Manager -- -- 1976
Mr. Feng He Deputy General Manager -- -- 1967
Ms. Yan Zhang Deputy General Manager -- -- 1980

HENGRUI PHARMA

No. 38, Huanghe Road
Economic and Technological Development Zone
Lianyungang City, 222000
China
86 40 0828 3900 https://www.hengrui.com
Sector: 
Healthcare
Full Time Employees: 
20,238

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; training; investment advisory; technology development; project; information; and investing services, as well as the import and export of pharmaceutical products. Jiangsu Hengrui Medicine Co., Ltd. was founded in 1970 and is headquartered in Lianyungang City, China.

Corporate Governance

HENGRUI PHARMA’s ISS Governance QualityScore as of May 1, 2025 is 1. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 4; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 25, 2025 at 10:59 AM UTC

HENGRUI PHARMA Earnings Date

Recent Events

July 12, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers